Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (211)	2/26/1999 4:07:00 PM
From: James Silverman	Respond to of 3158

Andrx will get munched. Don't know when but the logical buyer is Watson, which holds 20% of ADRX. ADRX is likely to be first to market for a generic prilosec, have Cardizem locked up for now and have their secretive NDA programs to unveil. So plenty of room for growth before looking to tie the knot. I'm expecting a secondary offering in the near future. If so, that would probably point to independence for the time being. Here's my longshot munch candidate: PDLI.